icobrain aria

by icometrix NV  · Based in Belgium → — AI for Safer Alzheimer's Treatment Monitoring
Neurology Radiology

Contact vendor for pricing
Regulatory Status Disclosed

Overview

icobrain aria is an advanced AI-powered software developed by icometrix (now a GE HealthCare company) for the automated detection, measurement, and severity assessment of Amyloid-Related Imaging Abnormalities (ARIA) on brain MRI scans. Specifically designed for patients undergoing amyloid-targeting therapies for Alzheimer’s disease, icobrain aria helps radiologists and neurologists monitor potential side effects such as ARIA-E (edema/sulcal effusion) and ARIA-H (hemorrhage/superficial siderosis).

The software compares baseline MRI scans with post-dosing follow-up scans, providing robust, consistent, and standardized safety monitoring. Clinical validation studies have shown that icobrain aria shortens reading time, increases inter-reader radiological agreement, and enhances diagnostic performance for both general and specialized radiologists. It generates quantitative summary reports and annotated segmentation images to assist clinicians in making informed treatment decisions and optimizing patient safety. icobrain aria is the first and only FDA-cleared computer-aided detection and diagnosis (CADe/CADx) solution in neuroradiology for ARIA monitoring.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated detection of ARIA-E (edema/sulcal effusion)
  • Automated detection of ARIA-H (hemorrhage/superficial siderosis)
  • Quantification of ARIA measures
  • Severity assessment of ARIA-E and ARIA-H
  • Comparison of baseline MRI with post-dosing follow-up MRI
  • Standardized safety monitoring for anti-amyloid treatments
  • Reduced radiological reading time
  • Increased inter-reader radiological agreement
  • Enhanced diagnostic performance
  • Generates quantitative summary report

Use Cases

  • Monitoring side effects of amyloid-targeting therapies for Alzheimer's disease
  • Assessing ARIA in patients on anti-amyloid treatments
  • Supporting radiologists and neurologists in assessing ARIA
  • Optimizing patient safety in Alzheimer's treatment
  • Assisting with differential diagnosis of dementia (broader icobrain platform)
  • Evaluating eligibility for amyloid-targeting treatments (broader icobrain platform)

What Physicians Need to Know

Brain MRI Analysis
icobrain aria provides automated detection, quantification, and grading of Amyloid-Related Imaging Abnormalities (ARIA-E and ARIA-H) on brain MRI scans, specifically utilizing 2D FLAIR for ARIA-E (edema/sulcal effusion) and 2D T2* Gradient Echo (T2*-GRE) for ARIA-H (hemorrhage/superficial siderosis). It compares baseline and post-dosing follow-up MRI scans using a longitudinal neural network for robust safety monitoring.
Amyloid-Related Imaging Abnormalities (ARIA) Monitoring
The tool is specifically designed for the safety monitoring and management of Alzheimer's disease patients receiving amyloid-beta-directed monoclonal antibody therapies, which are associated with ARIA. It detects and measures ARIA-E (cerebral edema, sulcal effusion) and ARIA-H (microhemorrhages, superficial siderosis), providing a severity score according to clinical guidelines.
Triage Prioritization Speed
icobrain aria significantly improves radiologists' ability to detect and classify ARIA, boosting diagnostic sensitivity and accuracy, and reducing reading time compared to unassisted reads. This enhanced efficiency can streamline the assessment process for ARIA, which is crucial for timely treatment decisions in Alzheimer's therapy.
Physician Tip

icobrain aria serves as an assistive software tool, enhancing radiologists' performance in detecting and quantifying subtle ARIA-E and ARIA-H, which can be challenging to identify manually. It is particularly valuable for standardizing ARIA assessment and improving patient safety during amyloid-targeting Alzheimer's therapies, especially in settings with limited experience in ARIA detection. However, it is intended to be used as a concurrent reading aid and not to replace a radiologist's final diagnosis or clinical judgment.

icobrain aria is designed for seamless integration into existing hospital workflows. It accepts DICOM input from MRI scanners and generates outputs such as segmentation overlays, quantitative summary reports, and draft radiology reports in DICOM, HL7, and JSON formats. These outputs can be automatically pushed into Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and Electronic Medical Record (EMR) systems. Philips is integrating icometrix's AI software, including icobrain aria, into its BlueSeal MR scanners.

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Contact vendor for pricing
DeploymentCloud-based software, integrated with MRI systems (post-GE HealthCare acquisition).
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

icobrain aria received FDA 510(k) clearance (K240712) on November 7, 2024. It is a Class II AI software device approved for detecting, measuring, and grading Amyloid-Related Imaging Abnormalities (ARIA-E and ARIA-H) in Alzheimer's patients undergoing amyloid-targeting therapies.

Integrations
EHR Not specified
Specialties Neurology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate icobrain aria

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

NeurologyLive
FDA Clears Icobrain Aria, First AI Tool for Safer ARIA Detection in Alzheimer Treatment
Icobrain aria, an AI software, received FDA approval in November 2024 for detecting and grading ARIA in Alzheimer's treatments, enhancing patient safety by improving detection sensitivity and specificity.
2024-11
PR Newswire
FDA authorizes the first AI-driven MRI solution for safer Alzheimer's treatment
On November 7, 2024, the FDA granted icometrix clearance for icobrain aria, the first AI software approved for detecting, measuring, and grading amyloid-related imaging abnormalities (ARIA), a side effect of new amyloid-targeting therapies.
2024-11
icometrix
Market approval for icobrain aria - icometrix
Icometrix announced market approval for icobrain aria in several key regions including Europe, Israel, Japan, Switzerland, and the United Kingdom in September 2024, making it the first market-approved solution for monitoring ARIA in Alzheimer's disease.
2024-09
AuntMinnieEurope
Icometrix gains EU approval for ARIA monitoring AI software - AuntMinnieEurope
Icometrix received approval to market its icobrain aria software in Europe, Israel, Japan, Switzerland, and the U.K. in September 2024, with the software designed for automated quantification of ARIA.
2024-09
Neurology
Validation of Icobrain Aria - An AI-based Software Tool for Automated Detection and Quantification of Amyloid-related Imaging Abnormalities (S1.005) | Neurology
A study presented in April 2024 demonstrated that icobrain aria, an automated detection and diagnosis tool, significantly increased the sensitivity of ARIA detection by radiologists, potentially improving safety monitoring for patients on amyloid beta-directed monoclonal antibody therapies.
2024-04
PMC (JAMA Network Open)
Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities - PMC
This diagnostic study, published in February 2024, found that radiological reading performance for ARIA detection and diagnosis was significantly better when using the AI-based assistive software icobrain aria, highlighting its potential as a clinically important tool for safety monitoring in Alzheimer's patients.
2024-02
icometrix
icobrain aria: a breakthrough in Alzheimer's disease management and care - Icometrix
Icometrix announced in October 2023 the development of icobrain aria, an AI-powered solution for ARIA assessment, emphasizing its potential to optimize benefits and risks in Alzheimer's disease management.
2023-10
GE HealthCare
GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions
GE HealthCare announced its intent to acquire icometrix in September 2025, aiming to strengthen its neurology portfolio with icobrain aria, the first FDA 510(k) cleared AI solution for detecting side effects of amyloid-targeting therapies.
2025-09

Videos

Product demos, reviews, and walkthroughs for icobrain aria.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

Icobrain aria integrates by automatically analyzing baseline and follow-up brain MRI scans to detect, measure, and grade Amyloid-Related Imaging Abnormalities (ARIA-E and ARIA-H). It generates a quantitative summary report with severity ratings and annotated images, which can be integrated into PACS or EMR systems via icobridge for seamless access within existing clinical workflows.
Icobrain aria received U.S. FDA 510(k) clearance as a Class II AI software device in November 2024 for detecting and grading ARIA. It also holds market approvals in Europe, Israel, Japan, Switzerland, and the United Kingdom. While specific details on data privacy protocols beyond general integration into hospital systems are not extensively detailed in the provided snippets, icometrix, the developer, is a global leader in AI software for brain imaging, suggesting adherence to relevant healthcare data regulations.
Icobrain aria can exhibit false positives, such as mistaking stable microhemorrhages or motion artifacts for ARIA, and may occasionally miss microhemorrhages. It was primarily trained on 2D FLAIR and T2* sequences, making it less ideal for 3D FLAIR or SWI, and it does not segment macrohemorrhages larger than 1 cm.
Studies show that icobrain aria significantly increases radiologists' sensitivity in detecting ARIA-E and ARIA-H, particularly for mild cases, and improves inter-reader agreement. For example, sensitivity for ARIA-E detection increased from 71% to 87% with AI assistance.
Yes, other AI-powered tools for microhemorrhage or ARIA detection include NeuroQuant and Neurophet AquaAD, as well as NeuroQuant ARIA 5.0 from Cortechs.ai, which also received similar regulatory clearance. Icobrain aria is noted as the first FDA-cleared AI software specifically for detecting, measuring, and grading ARIA, offering a standardized approach to ARIA monitoring.
Icobrain aria is offered on a subscription-based pricing model, with costs typically based on the number of analyses performed. While specific figures are not provided, AI-assisted tools like icobrain are anticipated to reduce the labor and time intensity of ARIA monitoring, potentially leading to workflow efficiencies and cost savings in the long term.
Icobrain aria is designed as an assistive tool to augment, not replace, the radiologist's expertise. Radiologists must still make the final diagnosis, and a proposed workflow includes an initial independent interpretation followed by a review of AI findings to avoid 'cognitive offloading' and ensure comprehensive assessment.

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

More from icometrix NV

Icobrain
Icometrix NV
Neurology AI
Icobrain is an AI-powered software by Icometrix NV that analyzes brain MRI and CT scans to provide quantitative insights for neurological conditions such as multiple sclerosis, dementia, Alzheimer's, stroke, epilepsy, and traumatic brain injury. It is FDA-cleared and CE-marked, assisting clinicians in diagnosis, monitoring, and treatment assessment.
icobrain-ctp
Icometrix NV
Neurology AI
Icometrix icobrain-ctp is an AI-powered image processing software for CT perfusion scans of the brain, providing analysis and communication of dynamic imaging datasets to quantify tissue flow and blood volume parameters.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.